Interestingly, the combination of VIP antagonist and anti-PD-1 antibody significantly reduced tumor volume compared with the control and tended to further attenuate tumor growth compared with the VIP antagonist or anti-PD-1 antibody alone (Fig. 4A). Here, VIP is linked to neoplasm.